IKZF1 mutations/deletions and FLT3-ITD mutations predicted poor outcomes in AML patients with CEBPAbZIP-inf mutations in addition to a high WBC count, lower hemoglobin concentration, non-intensive induction therapy, and MRD positivity after the first consolidation. This evidence concerns the gene FLT3 and acute myeloid leukemia.